Up to two postdoctoral positions are available immediately in the laboratory of Dr. Cheryl Wellington, Department of Pathology and Laboratory Medicine, University of British Columbia.
Dr. Wellington directs a unique research program in Canada that focuses on diseases of the central nervous system from a whole-body perspective. Building on her training in lipoprotein biology and neurodegenerative disease, Dr. Wellington has become internationally recognized for her contributions on apolipoprotein E (apoE) function in Alzheimer’s Disease (AD). ApoE is the most important genetic risk factor for the common type of AD and is emerging as a key therapeutic target. Dr. Wellington’s group has shown that the amount of lipids carried by apoE is directly correlated with efficient degradation of Aβ peptides, which are the toxic species that accumulate as amyloid plaques in the AD brain. Current efforts in this area include drug discovery efforts for apoE modulators, elucidating functions of apoE other than Aβ clearance in AD, and understanding how lipoproteins other than apoE contribute to AD.
Traumatic Brain Injury (TBI) is the leading cause of death and disability in persons under 40 years of age in North America. TBI is also a major risk factor for AD, and post-mortem studies of TBI brain tissue reveal common features (and some distinguishing characteristics) with AD. Interest in learning more about the neuropathology of TBI is surging, particularly with respect to the acute and long-term effects of concussions, which are mild TBIs that have until now been considered largely benign and self-resolving. However, multiple repeated concussions such as those experienced by athletes in high contact sports such as boxing, football and hockey, is now recognized to lead to a distinct neuropathological disease called Chronic Traumatic Encephalopathy (CTE). Dr. Wellington has launched several research projects in this area, including understanding the role of apoE on repeated concussions in mouse models, investigating the relationship between TBI and AD risk in animal models and in human subjects, and in using biomechanical engineering principles to design better models of TBI that more closely resemble human injury.
Dr. Wellington takes an integrative approach in her research projects and is dedicated to providing an outstanding training environment where young scientists will reach their full potential.
Candidates must have completed a PhD and/or MD degree and have a demonstrated publication record of first-author contributions in one or more relevant scientific fields, including lipoprotein biology, AD or TBI. Candidates must posses exceptional skills in critical thinking, oral and written communication, initiative, independence and work ethic.
If you are interested in applying for a position in Dr. Wellington’s laboratory, please send your CV, statement of career goals, representative publications and three letters of reference to eval(unescape('%64%6f%63%75%6d%65%6e%74%2e%77%72%69%74%65%28%27%3c%61%20%68%72%65%66%3d%22%6d%61%69%6c%74%6f%3a%63%68%65%72%79%6c%40%63%6d%6d%74%2e%75%62%63%2e%63%61%22%3e%63%68%65%72%79%6c%40%63%6d%6d%74%2e%75%62%63%2e%63%61%3c%2f%61%3e%27%29%3b')). The closing date for this competition is Jan 31, 2013.
University of British Columbia